STEMI

ZOLL Receives Innovative Technology Contract from Vizient for TherOx SuperSaturated Oxygen (SSO2) Therapy

Retrieved on: 
Tuesday, April 2, 2024
Surgery, Medical Devices, Hospitals, Health, Cardiology, Angioplasty, Asahi Kasei, Patient, Cardiac muscle, Facial muscles, Mortality, Splenic infarction, AUC, STEMI, LAD, Heart, Safety, Patient safety, FDA, Nursing

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has received an Innovative Technology contract from Vizient, Inc. , the nation’s largest provider-driven healthcare performance improvement company.

Key Points: 
  • ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has received an Innovative Technology contract from Vizient, Inc. , the nation’s largest provider-driven healthcare performance improvement company.
  • Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient’s Innovative Technology Program.
  • Through its Innovative Technology Program , Vizient works with customer-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare.
  • Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.

The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack

Retrieved on: 
Wednesday, February 7, 2024
Partnership, BHP, Hospital, Trial of the century, STEMI, Heart, Clinical trial, Percutaneous coronary intervention, Patient, Safety, Splenic infarction, Queen Elizabeth Hospital, University, Northern General Hospital, University of Birmingham, Myocardial infarction, Stroke, Associate, Pharmaceutical industry

February 7, 2024, the University of Birmingham and Acticor Biotech are proud to announce the first patient treated in the LIBERATE clinical study to evaluate glenzocimab efficacy in myocardial infarction.

Key Points: 
  • February 7, 2024, the University of Birmingham and Acticor Biotech are proud to announce the first patient treated in the LIBERATE clinical study to evaluate glenzocimab efficacy in myocardial infarction.
  • In 2022, the University of Birmingham and Acticor Biotech signed a partnership agreement to evaluate glenzocimab efficacy in myocardial infarction in a new clinical trial called LIBERATE.
  • This study is exploring the potential of glenzocimab in reducing the type of blood clotting responsible for heart damage during heart attacks.
  • Birmingham Health Partners is a strategic alliance between five organisations who collaborate to bring healthcare innovations through to clinical application:

Faraday Pharmaceuticals Announces Agreement with FDA on Interim Analysis of Phase 3 IOCYTE AMI-3 Trial Data and EU Notice of Intention to Grant Patent

Retrieved on: 
Thursday, January 4, 2024
SPA, Food, Reperfusion injury, PCI, STEMI, FDA, European, Patent, Ischemia, Death, European Patent Convention, Michael Faraday, Safety, EPO, Patient, Heart failure, Pharmaceutical industry

The company also announced its receipt of a notice of “intention to grant” its FDY-5301 patent application from the European Patent Office (EPO), allowing for the expansion of FDY-5301’s protection across the European Union (EU) into 2035.

Key Points: 
  • The company also announced its receipt of a notice of “intention to grant” its FDY-5301 patent application from the European Patent Office (EPO), allowing for the expansion of FDY-5301’s protection across the European Union (EU) into 2035.
  • The SPA amendment optimizes the timing, based on the study’s current enrollment rate, and expands the data set of the interim analysis.
  • The trial is being conducted under a Special Protocol Agreement reached with the U.S. Food and Drug Administration.
  • For more information on the IOCYTE AMI-3 Phase 3 please visit ClinicalTrials.gov and reference Identifier NCT04837001 .

Human medicines European public assessment report (EPAR): Inhixa, enoxaparin sodium, Date of authorisation: 15/09/2016, Revision: 26, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Marketing, Liver, Coronary thrombosis, INN, Risk, Pulmonary embolism, STEMI, ATC, DVT, Unstable angina, Bleeding, International, ASA, Myocardial infarction, Antithrombin, Language, Heart, Stroke, European Medicines Agency, Infection, Extracorporeal, Sodium oxide, Rheumatology, Select, Chest pain, Patient, Aspirin, Vein, Safety, Anatomy, Medicine, Leg, Deep vein thrombosis, IIA, Sodium, Skin, Birth control

Human medicines European public assessment report (EPAR): Inhixa, enoxaparin sodium, Date of authorisation: 15/09/2016, Revision: 26, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Inhixa, enoxaparin sodium, Date of authorisation: 15/09/2016, Revision: 26, Status: Authorised

Nantworks AirStrip® and GE HealthCare Announce Agreement to Commercialize Integrated Patient Monitoring and Cardiac Data Visualization for Healthcare Systems

Retrieved on: 
Monday, December 4, 2023
Software, Managed Care, Professional Services, Telemedicine, Virtual Medicine, Apps, Applications, Technology, Hospitals, Artificial Intelligence, Health Technology, Data Analytics, Cardiology, Health, ECG, Pressure, STEMI, NantWorks, Patient, Multimedia, Creative, Communication, Environment, Health care, Aerodrome, AI, Cardiac output, Data, Vital signs, GE HealthCare, Wireless ambulatory ECG, Pharmaceutical industry, Medical imaging

GE HealthCare is now the exclusive distributor of AirStrip Cardiology and Patient Monitoring solutions in the U.S., offering data visualization technology that healthcare systems can purchase together.

Key Points: 
  • GE HealthCare is now the exclusive distributor of AirStrip Cardiology and Patient Monitoring solutions in the U.S., offering data visualization technology that healthcare systems can purchase together.
  • The combination of GE HealthCare and AirStrip provides a tightly integrated toolset under one solution set.
  • It brings together the wide range of GE HealthCare’s innovative and accurate ECG, cardiac output, and patient monitoring products with AirStrip’s advanced data visualization and monitoring capabilities - all available to clinical care teams on mobile devices and the web.
  • “We are proud to be the exclusive distributor of AirStrip’s innovative cardiac and monitoring technology,” said Catherine Estrampes, President and CEO, U.S. and Canada, GE HealthCare.

Avertix Data Presented at TCT 2023 Shows 150% Increase in Medication Adjustments of Antiarrhythmics for High-Risk Heart Attack Survivors

Retrieved on: 
Tuesday, October 24, 2023
Patient, FDA, American College, Harvard Medical School, Splenic infarction, Beth Israel Deaconess Medical Center, History, Physician, Treatment, FACC, Cardiology, Acute coronary syndrome, Research, STEMI, Prescription, Risk, ACS, Coronary occlusion, FHRS, Safety, TCT, System, Vein, American College of Cardiology, Pharmaceutical industry, Medical device, Guardian, Electrophysiology

EATONTOWN, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), creator of the world’s first and only real-time heart attack detection and patient alerting system designed to improve long-term management and outcomes of recurrent events in high-risk patients who have survived one or more heart attacks, announced The Guardian System™ data was presented today at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. The study found an increase of more than 150% in new administration or titration of medications related to rate and rhythm abnormalities in patients whose Guardian™ alarms were activated compared to patients whose alarms were off.

Key Points: 
  • The Guardian System, the first and only FDA-approved implantable heart attack detection and warning system, also alerts patients in real-time of abnormal heart rates and rhythms and provides a recent history of intracardiac recordings.
  • “This data has provided us with valuable insights into addressing the care needs of high-risk Acute Coronary Syndrome (ACS) patients,” said Dr. Kaplan.
  • “With a career-long commitment to improving patient wellbeing and advancing cardiovascular research, The Guardian System is changing the paradigm for heart attack survivors,” said Dr. Gibson.
  • In addition to endpoints assessing ACS events, the trial collected data on medication usage and adjustments.

Registered Nurses & Health Care Workers Launch Five-Day Strike Against Prime's St. Francis Medical Center Starting on October 9

Retrieved on: 
Sunday, October 8, 2023
St. Francis Medical Center, Health, Public, Prime Healthcare Services, American Federation of State, County and Municipal Employees, Registered nurse, Social, Stroke, Trauma, Alabama Department of Public Health, The Book of the Unnamed Midwife, ER, Case management (US healthcare system), Hospital, RNS, STEMI, Pharmacist, LOS, RN, Optometry, USC, ICU, Under Secretary of Defense for Personnel and Readiness, Public health, Practitioner, SEIU, Nursing, UCLA, AFL-CIO, St. Francis Medical Center (Lynwood), PPE, Medical Center, St. Francis

LOS ANGELES, Oct. 8, 2023 /PRNewswire/ -- Nearly all essential medical personnel at St. Francis Medical Center will walk out at 6:30 a.m. on Monday, October 9, to join the strike lines against Prime Healthcare (which owns hospitals in fourteen states), where they will march, picket, and chant for five days to protest chronically dangerous short staffing and patient care practices, along with unfair labor practices such as bad faith bargaining, threats, and attacks on workers' rights.

Key Points: 
  • 2017 – 2019 – RN turnover at St. Francis was 24.01%
    2020 – 2022 – RN turnover at St. Francis more than doubled to 50.42%
    The average replacement cost of one RN is $46,000.
  • The striking workers include 600 registered nurses represented by UNAC/UHCP and 900 other health care workers represented by SEIU-UHW: nursing assistants, medical assistants, vocational nurses, emergency room technicians, respiratory therapists, environmental services aides, and more.
  • St. Francis Medical Center is one of the busiest hospitals in Los Angeles County, with the only level II trauma, stroke, and STEMI center for many miles around.
  • Registered Nurses and allied health care workers strike St. Francis Medical Center
    Strikers return to work at 6:30 a.m. Saturday, October 14
    3630 E. Imperial Hwy, Lynwood, CA 90262 Imperial Highway & Martin Luther King, Blvd
    Hundreds of nurses and other health care workers in scrubs, uniforms, union gear, with allies, marching and chanting with picket signs
    Note for morning shows: Nurses will be available for live interviews beginning around 6:30 a.m.

STRIKE - RNs and Almost All Health Care Staff to Strike St. Francis Medical Center 10/9 - 10/13

Retrieved on: 
Thursday, September 28, 2023
California Department of Public Health, American Federation of State, County and Municipal Employees, ER, SEIU, St. Francis Medical Center, Harbor–UCLA Medical Center, RNS, National Labor Relations Board, Case management (US healthcare system), Health care, Stroke, Byington, The Book of the Unnamed Midwife, STEMI, Ambulance, Level 2, Optometry, LA County+USC Medical Center station, Complaint, Social, Pharmacist, Public health, Hospital, Patient, Practitioner, Nursing, ULP, RN, CDPH, ICU, UCLA, Health, Trauma, AFL-CIO, Bankruptcy, National Union, St. Francis

LOS ANGELES, Sept. 28, 2023 /PRNewswire/ -- Most of the essential medical personnel at St. Francis Medical Center in Lynwood, California, will go on strike from Monday, October 9 through Friday, October 13. The unions representing 600 registered nurses (UNAC/UHCP) and nearly all the medical support staff—nursing assistants, medical techs, and more (SEIU-UHW)—presented the legally required 10-day notice yesterday informing hospital management and Prime Healthcare, the hospital's owner, of the looming strike.

Key Points: 
  • St. Francis Medical Center is one of the busiest hospitals in Los Angeles County, with the only Level II trauma, stroke, and STEMI (heart attack response) center for many miles around.
  • This is where you will be coming," said Scott Byington, RN, president of the UNAC/UHCP affiliate at St. Francis.
  • Byington is a mobile critical care nurse at St. Francis, which means he's part of a crew that responds to trauma emergencies throughout the hospital.
  • UNAC/UHCP is affiliated with the National Union of Hospital and Health Care Employees and the American Federation of State, County and Municipal Employees, AFL-CIO.

The UK Regulatory Agency (MHRA) Approved the Protocol of LIBERATE Study, the First Clinical Trial Evaluating Glenzocimab for Heart Attacks

Retrieved on: 
Thursday, September 7, 2023
Health, Other Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Percutaneous coronary intervention, Northern General Hospital, Queen Elizabeth Hospital Birmingham (1933–2010), Partnership, University, Therapy, Myocardial infarction, BHP, Clinical trial, Splenic infarction, Sri Jayadeva Institute of Cardiovascular Sciences and Research, STEMI, Associate, Trial of the century, Journal, Patient, University of Birmingham, University Hospitals Birmingham NHS Foundation Trust, Journal of Thrombosis and Haemostasis, Thrombosis, Hospital, Queen Elizabeth Hospital, Safety, Pharmaceutical industry

September 7th, 2023, the University of Birmingham and Acticor Biotech (Paris:ALACT) announce the full regulatory approval of LIBERATE clinical study.

Key Points: 
  • September 7th, 2023, the University of Birmingham and Acticor Biotech (Paris:ALACT) announce the full regulatory approval of LIBERATE clinical study.
  • In 2021, the University of Birmingham and Acticor Biotech signed a partnership agreement to evaluate glenzocimab efficacy in myocardial infarction in a new clinical trial called LIBERATE.
  • This new clinical trial is based on a long-standing collaboration between Acticor Biotech and the University of Birmingham.
  • We are very pleased to receive regulatory approval to launch the LIBERATE clinical trial to investigate whether glenzocimab can reduce the type of blood clotting that causes heart damage during heart attacks.

Fight for Safe Care: Hundreds of Nurses and Allies Will Picket St. Francis Medical Center on August 29

Retrieved on: 
Monday, August 28, 2023
American Federation of State, County and Municipal Employees, St. Francis Medical Center, RNS, Personal protective equipment, Case management (US healthcare system), Health care, Stroke, The Book of the Unnamed Midwife, STEMI, Nursing, National Union, Optometry, Social, Pharmacist, PPE, Practitioner, RN, St. Francis, Hospital, Health, Trauma, AFL-CIO, Bankruptcy

Now the hospital is dangerously understaffed nearly every day on every shift.

Key Points: 
  • Now the hospital is dangerously understaffed nearly every day on every shift.
  • Now, the nurses are speaking out to alert the public—and hoping to turn negotiations around before management's stonewalling forces a strike.
  • Nurses will be available to tell their stories about the patient care hazards at St. Francis and how they're fighting for safer patient care.
  • UNAC/UHCP is affiliated with the National Union of Hospital and Health Care Employees and the American Federation of State, County and Municipal Employees, AFL-CIO.